Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 81
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O23EFA6A9C2EN
Leaflet:

Download PDF Leaflet

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
  • The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects
  • The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) Overview
Therapeutics Development
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies
Onychomycosis (Tinea Unguium) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Onychomycosis (Tinea Unguium) - Products under Development by Companies
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Almirall, S.A.
Anacor Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
Blueberry Therapeutics Ltd
Crescita Therapeutics Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Hexima Limited
Meiji Seika Pharma Co., Ltd.
Moberg Pharma AB
NAL Pharmaceuticals Ltd.
Nihon Nohyaku Co., Ltd.
Novabiotics Limited
Novan, Inc.
Viamet Pharmaceuticals, Inc.
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AN-2718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luliconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015
Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015
Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit
Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation
Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015
Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Almirall, S.A., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics, Inc., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Crescita Therapeutics Inc., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Novan, Inc., H2 2016
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2016
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..1), H2 2016
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H2 2016
Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Almirall, S.A.
Anacor Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
Blueberry Therapeutics Ltd
Crescita Therapeutics Inc.
Eisai Co., Ltd.
Helix BioMedix, Inc.
Hexima Limited
Meiji Seika Pharma Co., Ltd.
Moberg Pharma AB
NAL Pharmaceuticals Ltd.
Nihon Nohyaku Co., Ltd.
Novabiotics Limited
Novan, Inc.
Viamet Pharmaceuticals, Inc.
Skip to top


Ask Your Question

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: